Literature DB >> 18812697

Electroporation at low voltages enables DNA vaccine to provide protection against a lethal H5N1 avian influenza virus challenge in mice.

Yu Zhou1, Fang Fang, Jianjun Chen, Huadong Wang, Haiyan Chang, Zhongdong Yang, Ze Chen.   

Abstract

OBJECTIVE: Electroporation has been proved to enhance the efficacy of intramuscular delivery of DNA. However, the process of electroporation causes pain and discomfort to the patient receiving the treatment. Higher the electroporation voltages inflict greater pain, and this limits the circumstances in which the technique can be used clinically. The voltages generally used for electroporation in animals range from 100 to 1,200 V/cm. We studied the effect of DNA vaccination when electroporation was performed at lower voltages.
METHODS: BALB/c mice were immunized twice by electroporation, at a 3-week interval, with H5N1 virus hemagglutinin (HA) DNA. One week after the booster had been given, the mice were challenged with a lethal dose of mouse-adapted H5N1 virus. The immune effects of HA DNA were evaluated by the survival rate, lung virus titer, bodyweight change and antibody titer of the mice.
RESULTS: The higher the voltage used, the more able were the mice to survive the challenge. However, a significant degree of protection could also be achieved with a voltage as low as 5 V. When electroporation was performed at a voltage of 10 V, an immunization amount of 5 microg is enough for HA DNA to provide effective protection.
CONCLUSION: Low-voltage electroporation can induce immunity and protect mice effectively. There is, therefore, the potential to reduce the voltages currently used for DNA electroporation. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812697     DOI: 10.1159/000156483

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  4 in total

1.  Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.

Authors:  Han Lei; Zhina Sheng; Qian Ding; Jian Chen; Xiaohui Wei; Dominic Man-Kit Lam; Yuhong Xu
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Authors:  Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; André Maaske; Vladimir Temchura; Vanessa Heinecke; Drew Hannaman; Jan Buer; Christina Ehrhardt; Wiebke Hansen; Klaus Überla; Matthias Tenbusch
Journal:  Immunology       Date:  2015-04-30       Impact factor: 7.397

3.  Comparison of the Protective Efficacy of Neutralizing Epitopes of 2009 Pandemic H1N1 Influenza Hemagglutinin.

Authors:  Bo Peng; Na Peng; Yanan Zhang; Fenghua Zhang; Xuguang Li; Haiyan Chang; Fang Fang; Fuyan Wang; Fangguo Lu; Ze Chen
Journal:  Front Immunol       Date:  2017-08-31       Impact factor: 7.561

4.  Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.

Authors:  Viktoria Stab; Sandra Nitsche; Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; Andrea Wiechers; Bettina Tippler; Drew Hannaman; Christina Ehrhardt; Klaus Uberla; Thomas Grunwald; Matthias Tenbusch
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.